key: cord-0988438-tsqditt4
authors: Schiller Salton, Neta; Szwarcwort, Moran; Tzoran, Inna; Horowitz, Netanel A.; Zuckerman, Tsila; Horesh, Nurit; Shachor‐Meyouhas, Yael; Hussein, Khetam; Lavi, Noa
title: Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
date: 2021-10-16
journal: Am J Hematol
DOI: 10.1002/ajh.26373
sha: 8ca1a8705cf370320b9b2fbb6991c410b7122b65
doc_id: 988438
cord_uid: tsqditt4

nan

recovered, 2 had mild disease). Two patients displayed a negative serological result 1 month after second vaccination, which converted to positive following their COVID-19 resolution. One patient was seropositive at 1 month after vaccination and his disease course was mild. The patient who died did not undergo serological evaluation.

T A B L E 1 Correlation of anti-myeloma therapy and blood workup with serological response 1 month after second anti-COVID-19 vaccination 

The authors have no conflicts to declare.

Neta Schiller Salton performed research, interpreted the data, and 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and metaanalysis of 3377 patients

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

SARS-CoV-2 vaccines in patients with multiple myeloma

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network